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a  b  s  t  r  a  c  t
Peripheral ulcerative keratitis is caused by an inﬂammatory and destructive process of the
perilimbal peripheral cornea. This inﬂammation is due to immune complex deposition in
this region of the cornea and in adjacent vessels. It can be idiopathic, or a manifestation of
systemic disease such as rheumatoid arthritis, vasculitis of small vessels associated with
ANCA, relapsing polychondritis, systemic lupus erythematosus and Crohn’s disease. Its
treatment includes the use of high-dose corticosteroids and, in some cases, the concomitant
use of immunosuppressants such as methotrexate, azathioprine, mycophenolate mofetil,
cyclophosphamide or cyclosporine. The use of immunobiological agents can be a strategy
in  cases of difﬁcult control. The authors describe the treatment of three patients who, after
failure with the use of corticosteroids or immunosuppressants, showed good response after
the  use of inﬂiximab.
© 2014 Elsevier Editora Ltda. All rights reserved.
Inﬂiximabe  é  eﬁcaz  em  ceratite  ulcerada  periférica  de  difícil  controle.  Um




r  e  s  u  m  o
Ceratite ulcerada periférica é causada por um processo inﬂamatório e destrutivo da córnea
periférica perilimbar. Essa inﬂamac¸ão se deve à deposic¸ão de imunocomplexos nessa região
da  córnea e nos vasos adjacentes a ela. Pode ser idiopática ou uma  manifestac¸ão de doenc¸a
Anticorpo monoclonal sistêmica como artrite reumatoide, vasculites de pequenos vasos associadas ao ANCA, à
policondrite recidivante, ao lúpus eritematoso sistêmico e à doenc¸a de Crohn. O trata-
mento inclui o uso de corticoide em dose alta e em alguns casos o uso concomitante de
imunossupressores, como metotrexate, azatioprina, micofenolato mofetil, ciclofosfamida
ou  ciclosporina. O uso de agentes imunobiológicos pode ser uma estratégia nos casos de
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difícil controle. Os autores descrevem o tratamento de três pacientes que após falha ao uso
de  corticoide ou imunossupressores apresentaram boa resposta após o uso de inﬂiximabe.













































he peripheral cornea is situated very close to the conjunc-
iva, which has the critical elements for generating an immune
esponse. As compared with the central cornea, this corneal
egion has a greater number of inﬂammatory cells, allowing
he formation of immune complexes.1
Peripheral ulcerative keratitis is a destructive process that
nvolves inﬂammation of the perilimbal cornea1 and overlying
pithelial defects.2 The diseases commonly involved in this
egion are Mooren ulcers, autoimmunity against the cornea
tself,1 or manifestations of systemic disease,3 especially
heumatoid arthritis and vasculitides.4 When the peripheral
orneal ulcer is accompanied by necrotizing scleritis, perfora-
ion and consequently loss of vision can occur, which conﬁrms
he severity of this eye disease.
The treatment of this disease includes corticosteroids in
he acute phase and immunosuppressants in severe periph-
ral ulcerative keratitis, especially when associated with
ystemic disorders. Recently, the use of biological agents such
s rituximab, an antibody against CD20, and monoclonal anti-
odies against pro-inﬂammatory cytokine TNF alpha (tumor
ecrosis factor) has been shown to be an alternative.5–8
ase  reports
ase  1
ale patient, 20 years old, ﬁve years with recurrent red
ye and eye pain. An ophthalmological investigation found
he presence of peripheral ulcerative keratitis; the patient
as introduced in topical steroids, prednisone 20 mg/day
nd NSAIDs, without improvement. The picture evolved
ith increased peripheral ulceration, signiﬁcant conjunctival
nﬂammatory component, and increased pain. Two years ago
he patient received pulse therapy with methylprednisolone
 g/day for three days, and inﬂiximab was started at a dose
f 3 mg/kg at weeks zero, two and six, and then every eight
eeks, with signiﬁcant improvement of ulceration, hyper-
mia, and eye pain. Currently, the patient remains in the use
f only inﬂiximab, without recurrence of ocular inﬂammation.
ase  2
emale patient, 59 years old, diagnosed with peripheral ulcer-
tive keratitis for 10 years, but with symptoms of red eye
nd eye pain for 17 years. Treated with prednisone 40 mg/day
nd cyclosporin 3 mg/kg/day, with no response. During evo-
ution, methotrexate was associated with the medication,
nd due to non-improvement, methotrexate was replaced by
zathioprine. After a further failure of this new therapeutic
ombination (azathioprine and cyclosporine), three years agoinﬂiximab was started at a dose of 3 mg/kg at intervals of eight
weeks, with excellent response. Currently, the patient exhibits
corneal injury healing, with no evidence of recurrence of per-
ilesional inﬂammation.
Case  3
Male patient, 36 years old. Started seven years ago with recur-
rent episodes of severe eye pain, red eye and photophobia.
An ulcer was diagnosed in perilimbar cornea, with frequent
recurrence. The patient was treated with prednisone 60 mg
and cyclosporine; without response. Due to clinical worsen-
ing of his eye disease and the difﬁculty in reducing the dose
of corticosteroids, inﬂiximab was started at a dose of 3 mg/kg
at weeks zero, two and six and then every eight weeks, with
almost complete resolution of the corneal lesion.
Discussion
Peripheral ulcerative keratitis is a condition characterized by
inﬂammation of the peripheral cornea that causes ulcera-
tion of difﬁcult resolution,2 which can occur in isolation or
as part of a systemic inﬂammation.9,10 Multiple infections
can determine corneal ulcer; thus, the differential diagnosis
is critical.10
Approximately 50% of cases of non-infectious periph-
eral ulcerative keratitis are associated with some connective
tissue disease,5,11 especially rheumatoid arthritis. Other eti-
ologies include polyarteritis nodosa, relapsing polychondritis,
vasculitis associated with ANCA, for example, granulomato-
sis with polyangiitis (Wegener’s) and granulomatosis with
eosinophilic polyangiitis (Churg-Strauss syndrome).5,9,12 A
study published in 2012 showed that 211 of 701 patients with
granulomatosis with polyangiitis had some ocular involve-
ment in the diagnosis and 147 others developed the condition
in the course of the disease. Among the changes found,
peripheral ulcerative keratitis was observed.13
The corneal signals are similar in those various diseases
causing the problem: red eye, pain, photophobia and corneal
opacity.5,9 This condition may occur after several years of sys-
temic disease, or may be its ﬁrst manifestation.9,12
Peripheral ulcerative keratitis is associated with high visual
and systemic morbidity. Its complications are perforation of
the cornea and decreased visual acuity. Inﬂammation of the
eye may be an initial presentation of a systemic inﬂamma-
tory disease with subclinical involvement of other organs and
systems of the human body.9
The treatment for this condition is difﬁcult and is based on
the severity of corneal symptoms and on the extent of extraoc-
ular disease.9 Initially, the treatment consists of topical and
systemic corticosteroids, such as prednisone at 1 mg/kg/day;
this treatment might not be able to promote remission.3,4,7 The
use of immunosuppressants may be tempted, in view of the
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severity of the disease and the risk of vision loss.14 Cyclophos-
phamide PO (2 mg/kg/day) or in monthly intravenous pulses
may be used in conjunction with glucocorticoids in cases with
risk of perforation or in the context of systemic vasculitides.
Some patients may respond to the use of methotrexate, as
demonstrated in a case report of a 25 year-old woman who
had a signiﬁcant improvement of idiopathic peripheral ulcer-
ative keratitis with 10 mg  of methotrexate per week and, after
four weeks, the dose was increased to 25 mg,  with excellent
response.15 Cyclosporine is an option to be attempted, with
reports of response in cases of Mooren’s ulcer.16 Furthermore,
the use of immunobiological products such as rituximab,
a monoclonal antibody against CD20 expressed by lympho-
cytes B in granulomatosis with polyangiitis,5 and especially
inﬂiximab, an anti-TNF, can produce a quick response in the
suppression of corneal inﬂammation and of pain, thus deter-
mining the clinical improvement in cases of difﬁcult control,
such as in the patients here reported.5,7,8,13,15,17 The cytokine
TNF is important in the pathogenesis of peripheral ulcerative
keratitis, both in idiopathic cases, as in those associated with
rheumatoid arthritis or vasculitis. TNF stimulates the activity
of metalloproteinases, in particular MMP-9, which has been
conﬁrmed in a dose-dependent manner in cultured human
corneal epithelial cells. The increased expression and activ-
ity of MMP-9 were demonstrated in samples of human cornea
with ulcerative keratitis. Thus, the inhibition of the cytokine
TNF with the use of monoclonal antibodies can reduce the
inﬂammation and destruction of extracellular matrix and
corneal collagen degradation due to an unregulated activity
of matrix metalloproteinases.18–20
Odorcic et al. in their study reported that there is not a rec-
ommended dose of inﬂiximab in cases of peripheral ulcerative
keratitis, and that reducing the interval between infusions to
once every four weeks may be necessary.4 Galor et al. showed,
in a study, stability in visual acuity in 68% of 12 patients
with rheumatoid arthritis associated with peripheral ulcerat-
ive keratitis, following treatment with cyclophosphamide or
methotrexate.9
In the three cases here presented, we had favorable
responses to inﬂiximab in the treatment of ulcerative keratitis,
prescribed after failure of corticosteroids and/or immunosup-
pressants, like other publications. Moreover, there was no
recurrence of peripheral ulcerative keratitis in any of the three
patients reported by us. All three cases showed no association
with connective tissue diseases. Randomized, controlled trials
with a larger number of cases will give more  support for the
use of biologic therapy, in particular anti-TNF, in patients with
this condition.Conﬂicts  of  interest
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